Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

J2O-MC-EKBC: KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults with Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Eli Lilly & Co., Eli Lilly & Co.

Enrolment target

100

Start

09 Feb 2023

Percent Change from Baseline in Lipoprotein (a) Lp(a) [Time Frame: Baseline to Week 12]

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.